Finland· FI-REL-REL60075

Lytgobi

A futibatinib product containing futibatinib, registered in Finland by Taiho Pharma Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC L01EN04

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedLytgobiATCL01EN04REGISTER NO.FI-REL-REL60075PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Futibatinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EN04 (futibatinib), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 8 of them publish a price we can compare per daily dose

Futibatinib · ATC L01EN04

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of futibatinib costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.36 in France to $366.73 in Switzerland — a ×1007 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Futibatinib · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$366.73
  • FR France$0.36
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Futibatinib
Manufacturer
Taiho Pharma Netherlands B.V.
Country
Finland (FI)
ATC code
L01EN04
ATC class
Futibatinib
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ff3e9757-2cd6-4408-ad8a-b496ef9b20cc
GET /v1/drugs/ff3e9757-2cd6-4408-ad8a-b496ef9b20cc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": null,
  "strength": "4 mg",
  "atc_label": "futibatinibi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/23/1741/001-003",
  "fimea_rel_id": "REL60075",
  "authorised_at": "2023-07-04"
}

See everything about futibatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.